Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research on biomarkers in "A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors"

Next Previous
Search
Trial Profile

Research on biomarkers in "A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors"

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Levofolinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms JACCRO CC-13AR

    • Most Recent Events

    • 21 Jul 2020 Status changed from recruiting to active, no longer recruiting.
    • 21 Jul 2020 Planned number of patients changed from 250 to 300.
    • 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology. Accrual of this trial will continue until the DEEPER trial is completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top